股东大会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-029 广州迈普再生医学科技股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）2023 年年度股东大会于 2024 年 5 月 10 日下午 14:30 以现场表决和网络投 票相结合的方式召开公司 2023 年年度股东大会。 1、会议召开时间：2024 年 5 月 10 日（星期五）下午 14:30； 2、会议召开地点：广州市黄埔区崖鹰石路 3 号迈普医学大厦会议 室。 3、会议召开方式：采取现场表决与网络投票相结合的方式。现场 会议召开时间：2024 年 5 月 10 日（星期五）下午 14:30。网络投票时 间：通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 5 股东大会决议公告 月 10 日上午 9:15-9:25， ...

回购股份进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-027 广州迈普再生医学科技股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股份回购基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2024 年 2 月 22 日召开第二届董事会第二十一次会议，审议通过了《关于 回购公司股份方案的议案》，公司拟使用自有资金通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股）用于员工持股计划 或者股权激励。公司拟用不低于人民币 1,000 万元且不超过人民币 2,000 万元（均含本数）。按照回购股份价格上限人民币 49 元/股， 回购金额下限人民币 1,000 万元测算，预计回购股份数量为 204,082 股，占公司当前总股本的 0.31%；按照回购股份价格上限人民币 49 元/股，回购金额上限人民币 2,000 万元测算，预计回购股份数量为 408,163 股，占公司当前总股本的 0.62%。本次回购股份的实施期限 为自公司董事会审议通过回购股份方案之日起不超过 12 个月 ...

证券代码：301033 证券简称：迈普医学 公告编号：2024-028 广州迈普再生医学科技股份有限公司 自愿增持公司股份时间过半的公告 关于公司部分高级管理人员自愿增持公司股份计划时 间过半的进展公告 公司董事、总经理王建华先生保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示 1、增持计划的基本情况：广州迈普再生医学科技股份有限公司 （以下简称"公司"）董事、总经理王建华先生拟自本次增持计划公 告披露之日起 6 个月内（即 2024 年 2 月 7 日至 2024 年 8 月 6 日，除 法律、法规及有关规定不得增持的期间外）通过深圳证券交易所交易 系统以集中竞价的方式增持公司股份，拟增持金额为人民币 25 万元 -50 万元。具体内容详见 2024 年 2 月 7 日披露的《关于公司实际控 制人、控股股东和部分董事、高级管理人员自愿增持公司股份计划的 公告》。 2、增持计划实施的进展情况：截至本公告披露日，王建华先生 的增持计划实施时间已过半。自增持计划公告之日至本公告披露日， 王建华先生通过深 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected increase in stock price relative to the benchmark index [12]. Core Insights - The company is set to see significant growth from new product launches, with a second growth curve beginning to take shape [8]. - In 2023, the company achieved a revenue of 231 million yuan, representing a year-on-year growth of 18.24%, and a net profit of 41 million yuan, up 13.89% [8]. - The company’s new products, particularly in the neurosurgery field, are expected to drive future growth, with a focus on expanding market share both domestically and internationally [9][15]. Financial Performance - The company reported a revenue of 57 million yuan in Q1 2024, a 28.59% increase year-on-year, and a net profit of 15 million yuan, up 91.19% [8]. - The revenue forecast for 2024-2026 is projected to be 290 million yuan, 388 million yuan, and 529 million yuan, with respective growth rates of 25.61%, 33.79%, and 36.34% [29]. - The net profit for the same period is expected to be 55 million yuan, 82 million yuan, and 121 million yuan, with growth rates of 35.27%, 47.61%, and 48.40% [29]. Product Analysis - The company’s main products include artificial dura mater patches, craniofacial repair systems, and new products such as absorbable regenerated oxidized cellulose hemostatic agents, which accounted for 60.47%, 26.41%, and 10.41% of revenue respectively [8]. - The craniofacial repair system saw a sales revenue of 60.97 million yuan in 2023, a 61.13% increase from the previous year, driven by growing demand in China [8]. - The absorbable regenerated oxidized cellulose hemostatic product has been used in over 100,000 clinical applications, breaking the long-standing import monopoly in the domestic market [8]. Market Positioning - The company has established a presence in nearly 90 countries and regions, with its products available in over 1,600 hospitals in China [9]. - The company is actively participating in bidding for medical glue products, which are expected to have significant market potential due to their unique properties [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% compared to the Shanghai Composite Index within the next six months [8][21]. Core Views - The company has shown strong revenue growth, with a reported revenue of 230.87 million yuan in 2023, representing an 18.2% increase year-on-year. The net profit attributable to shareholders was 40.88 million yuan, up 13.9% [15][17]. - The company is actively participating in centralized procurement, which is expected to accelerate product penetration and enhance market competitiveness. The introduction of new products is also anticipated to contribute significantly to revenue growth [6][17]. - The company’s sales and service network now covers nearly 90 countries and regions, with domestic and international revenues reaching over 180 million yuan and 50.046 million yuan, respectively, marking increases of 13.5% and 39.1% year-on-year [16][17]. Financial Performance - In 2023, the company achieved a revenue of 230.87 million yuan, with a year-on-year growth rate of 18.24%. The projected revenue for 2024 is 290.45 million yuan, reflecting a growth rate of 25.81% [10][17]. - The net profit attributable to shareholders for 2023 was 40.88 million yuan, with a projected increase to 52.35 million yuan in 2024, indicating a growth rate of 28.07% [10][17]. - The company’s earnings per share (EPS) are projected to be 0.79 yuan in 2024, increasing to 1.25 yuan in 2025 and 1.77 yuan in 2026, with corresponding price-to-earnings (P/E) ratios of 42.43, 26.89, and 19.01 respectively [10][17]. Business Segments - The primary revenue sources for the company are artificial dura mater (spinal) patches and craniofacial repair and fixation systems, accounting for 60.5% and 26.4% of total revenue, respectively. The dura mater patch segment saw a revenue decline of 3.5%, while the craniofacial segment experienced a significant growth of 61.1% [15][16]. - The commercialization of absorbable regenerated oxidized cellulose is expected to break the long-standing import monopoly in the neurosurgery market, with over 100,000 units used in clinical settings in 2023 [16]. - The company’s self-developed dura mater medical glue has unique properties that address existing product limitations, and its market penetration is expected to increase following the acquisition of necessary regulatory approvals [16].

Financial Performance - The company's revenue for Q1 2024 reached ¥57,206,084.70, representing a 28.59% increase compared to ¥44,485,769.60 in the same period last year[5] - Net profit attributable to shareholders was ¥14,944,754.94, a significant increase of 91.19% from ¥7,816,548.85 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥12,072,555.57, up 87.05% from ¥6,454,127.50 in the previous year[5] - Basic and diluted earnings per share both increased to ¥0.23, reflecting a growth of 91.67% compared to ¥0.12 in the same period last year[5] - The operating profit for the first quarter of 2024 was CNY 18,725,790.88, which is a significant increase from CNY 8,937,084.49 in the previous year[30] - The total operating revenue for the first quarter of 2024 was CNY 57,206,084.70, an increase of 28.6% compared to CNY 44,485,769.60 in the same period last year[28] - The total operating costs for the first quarter of 2024 were CNY 43,035,696.85, up 15.8% from CNY 37,145,242.79 in the previous year[28] - The net profit for the first quarter of 2024 reached CNY 14,944,754.94, representing an increase of 91.5% from CNY 7,816,548.85 in the same period last year[30] - The research and development expenses for the first quarter of 2024 were CNY 5,277,861.55, slightly down from CNY 5,661,139.07 in the previous year[28] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥778,037,172.67, a decrease of 1.13% from ¥786,969,032.68 at the end of the previous year[5] - The total current assets decreased slightly to CNY 265,898,793.41 from CNY 269,712,417.33, a decline of about 1.4%[25] - The company's inventory rose to CNY 30,344,255.45 from CNY 26,198,103.20, representing an increase of approximately 15.0%[25] - Non-current assets totaled CNY 512,138,379.26, down from CNY 517,256,615.35, indicating a decrease of about 1.0%[25] - The total liabilities as of the end of the reporting period were CNY 133,480,070.13, a decrease from CNY 151,110,819.27 in the previous year[28] - The total equity attributable to the parent company was CNY 644,557,102.54, an increase from CNY 635,858,213.41 in the previous year[28] Cash Flow - The net cash flow from operating activities was ¥15,888,191.38, down 18.25% from ¥19,434,599.35 in the same period last year[5] - Cash inflow from operating activities totaled $73,627,500.46, an increase from $66,508,610.90 in the previous period, representing an increase of approximately 3.34%[34] - Cash outflow from operating activities was $57,739,309.08, compared to $47,074,011.55 previously, indicating an increase of about 22.5%[34] - Net cash flow from operating activities decreased to $15,888,191.38 from $19,434,599.35, a decline of approximately 18.5%[34] - Cash inflow from investing activities was $116,272,060.74, down from $139,453,152.16, a decrease of about 16.6%[34] - Cash outflow from investing activities decreased to $99,454,056.35 from $164,086,920.91, a reduction of approximately 39.4%[34] - Net cash flow from investing activities improved to $16,818,004.39 from a negative $24,633,768.75, indicating a significant turnaround[34] - Cash flow from financing activities resulted in a net outflow of $9,983,352.37, compared to a larger outflow of $26,516,942.65 previously, showing a decrease of about 62.4%[36] - The net increase in cash and cash equivalents was $22,709,731.27, contrasting with a decrease of $31,925,042.71 in the prior period[36] - The ending balance of cash and cash equivalents rose to $49,380,615.16 from $12,837,726.43, reflecting a substantial increase[36] Shareholder Information - Major shareholders include Yuan Yuyu with 16.63% and Xu Tao with 16.53% of shares[14] - The top 10 shareholders hold a total of 50.61% of the company's shares, indicating significant ownership concentration[14] - Yuan Yuyu has pledged 4,910,000 shares, which is approximately 44.7% of his holdings[14] - As of March 31, 2024, the company reported that Yuan Meifu and his associates hold a total of 4,508,796 shares, representing 4.40% of the total shares[16] - Tang Ying and Ye Tao together hold 5.37% of the company after a transfer of 1,320,000 shares[16] - The company has a total of 10,987,847 shares held by Yuan Yuyu, with 10,922,547 shares subject to limited sale conditions[14] - The top 10 unrestricted shareholders include Shenzhen Kaiying Technology Co., Ltd. with 4,246,049 shares, representing 6.43%[14] - The report indicates that the company is actively managing its shareholder relationships and agreements to ensure compliance and transparency[16] - The company has not reported any additional related party relationships beyond those disclosed in the shareholder agreements[16] Other Information - The company implemented a second category of restricted stock for equity incentives starting in 2023, which positively impacted net profit growth[5] - The company reported a net profit of ¥1,769.73 million after excluding share-based payment expenses, marking a year-on-year increase of 126.41%[5] - The first quarter report was not audited, indicating that the financial figures are subject to further verification[37] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided data[28]

证券代码：301033 证券简称：迈普医学 公告编号：2024-026 广州迈普再生医学科技股份有限公司 关于举办 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 19 日在巨潮资讯网上披露了《2023 年年度报告》及《2023 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营 业绩、发展战略等情况，公司定于 2024 年 4 月 29 日（星期一） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办 2023 年度 网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2024 年 4 月 29 日（星期一）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 关于举办 2023 年度网上业绩说明会的公告 二、参加人员 董事长 袁玉宇先生 关于举办 2023 年度网上业绩说明会的公告 ...

董事会换届选举公告 广州迈普再生医学科技股份有限公司（以下简称"公司"、"迈普 医学"）第二届董事会任期将于 2024 年 6 月 15 日届满，根据《公司 法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律法规、规范性文件及《公司章程》的有关规 定，结合公司目前董事会构成及任职情况，为适应公司现阶段业务经 营及未来发展的实际需求，完善内部治理结构，公司决定进行董事会 换届选举。 一、董事会换届选举情况 公司于 2024 年 4 月 17 日召开第二届董事会第二十二次会议，逐 项审议通过了《关于公司董事会换届选举暨提名第三届董事会非独立 董事候选人的议案》《关于公司董事会换届选举暨提名第三届董事会 独立董事候选人的议案》。 证券代码：301033 证券简称：迈普医学 公告编号：2024-020 广州迈普再生医学科技股份有限公司 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为确保董事会的正常运行，在新一届董事会董事就任前，公司第 二 ...

提名人广州迈普再生医学科技股份有限公司董事会现就提名 袁庆 为广州迈普再生医学科技股份有限公司第三届董事会独立 董事候选人发表公开声明。被提名人已书面同意作为广州迈普再 生医学科技股份有限公司第三届董事会独立董事候选人(参见该 独立董事候选人声明)。本次提名是在充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不 良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则 对独立董事候选人任职资格及独立性的要求，具体声明并承诺如 下事项： 一、被提名人已经通过广州迈普再生医学科技股份有限公司 第二届董事会提名委员会或者独立董事专门会议资格审查，提 名人与被提名人不存在利害关系或者其他可能影响独立履职情 形的密切关系。 √ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四 十六条等规定不得担任公司董事的情形。 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独立董事管 理办 ...

内部审计工作制度 MP-CG-028,V2.0 内部审计工作制度 MP-CG-028,V2.0 广州迈普再生医学科技股份有限公司 内部审计工作制度 第一章 总则 第一条 为加强广州迈普再生医学科技股份有限公司（以下简称"公司"）内 部审计工作管理，提高审计工作质量，实现公司内部审计工作规范化、标准化，依 据《中华人民共和国审计法》《审计署关于内部审计工作的规定》《企业内部控制 基本规范》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》等相关法律、法规、规范性文件及 《广州迈普再生医学科技股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，结合公司的实际情况，制定本制度。 广州迈普再生医学科技股份有限公司 内部审计工作制度 二〇二四年四月 （四）确保公司公开的信息真实、准确、完整和公平。 第四条 内部审计部门依照国家法律、法规和规章以及《公司章程》，遵循客 观性、政策性和预防为主的原则，对本公司及控股、参股公司的经营活动和内部控 1 内部审计工作制度 MP-CG-028,V2.0 第二条 内部审计是指公司内部审计部门或人员对公司、控股子公司以及 ...